Leukemia, Myelodysplasia, Transplantation
Conference Coverage
Fixed-duration venetoclax-obinutuzumab superior to standard CLL therapy
CHICAGO – The immediately practice changing study offers a time-limited frontline option, one expert reported.
Conference Coverage
SC-PEG comparable to pegaspargase in young ALL/LL patients
CHICAGO – Patients who received SC-PEG had similar serum asparaginase activity, toxicities, and survival as patients...
Conference Coverage
Low intensity bridging may be best path to CAR T in adult ALL
CHICAGO – Researchers examined the use of high- and low-intensity chemotherapy bridging for patients waiting for treatment with a CD19-directed...
Conference Coverage
Combo produces ‘best response rate’ after first relapse in kids with AML
CHICAGO – CPX-351 followed by fludarabine, cytarabine, and filgrastim produced an overall response rate of 81%.
From the Journals
Venetoclax plus ibrutinib appears to suit elderly and high-risk patients with CLL
The combination of venetoclax and ibrutinib outperformed previous reports of either of the two agents alone.
From the Journals
Genetic analysis identifies prognostic markers in CLL
A single 11q22 deletion, lacking an ATM mutation on the other allele, had the shortest progression-free survival among patients with CLL who were...
Conference Coverage
NGS comparable to FC for minimal residual disease assessment
NEW ORLEANS – NGS of peripheral blood proved at least as effective as flow cytometry for assessing MRD in children and young adults with B-ALL who...
News
FDA approves venetoclax/obinutuzumab combo for CLL
Venetoclax/obinutuzumab was compared with venetoclax/chlorambucil in the CLL14 study and showed superior progression-free survival in previously...
Case-Based Review
Management of Late Pulmonary Complications After Hematopoietic Stem Cell Transplantation
Hematopoietic stem cell transplantation (HSCT) is increasingly used to treat hematologic malignancies as well as nonmalignant diseases and solid...
News
FDA panel not ready to recommend quizartinib approval for FLT3-ITD+ AML
SILVER SPRING, MD. – A small clinical benefit, questions about the validity of the data, and concerns about cardiovascular adverse events point to...
Conference Coverage
Master trial seeks to aid drug development for pediatric AML
NEW ORLEANS – “What we see in childhood AML is a lot different than what we see in adult AML, and this challenges the paradigm that we have...